International journal of cancer and clinical research最新文献

{"title":"Expression of P53 and Prognosis in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)","authors":"L. Amlani, E. Bellile, M. Spector, Joshua D Smith, C. Brenner, L. Rozek, Ariane Nguyen, Katie R. Zarins, Daffyd G. Thomas, J. Mchugh, Jeremy M. G. Taylor, T. GregoryWolf","doi":"10.23937/2378-3419/1410122","DOIUrl":"https://doi.org/10.23937/2378-3419/1410122","url":null,"abstract":"Introduction: Mutation of TP53 is the most common genetic abnormality in head and neck squamous cell carcinoma (HNSCC) and results in an accumulation and expression of p53 protein in tumor cells. Disruptive TP53 mutations are consistently associated with poor prognosis but correlations of p53 expression with mutation or prognosis have been variable and the usefulness of p53 as a target for immunotherapy is unknown. Favorable prognosis is associated with the accumulation of T lymphocytes (TILs) in the tumor microenvironment and an immune response to p53 has been suggested by demonstration of antibodies to p53 and p53-restricted cytotoxic cells in patients with HNSCC. To investigate if p53 expression is related to accumulation of TILs, p53 expression was measured in a prospective cohort of patients with HNSCC and correlations with TILs and prognosis were determined. Methods: Studied were 534 previously untreated patients (n) with oral cavity (273), oropharynx (158), larynx (81) or hypopharynx (22) cancers. Expression of p53, p21, and p16 and levels of T cell infiltrates (CD4, CD8, FoxP3) were assessed by immunohistology in tissue microarrays from biopsy specimens. HPV testing by routine pathology was available for 401 patients. Associations with clinical variables were tested using Kruskal-Wallis tests (p53, p21) or Chi-square test (p16). Kaplan-Meier and Cox regression methods were used to evaluate univariable and multivariable associations of protein expression with TIL levels and overall survival (OS) and disease specific survival (DSS) after adjusting for known prognostic factors. Median follow up was 44 months. Results: Higher p53 protein expression was associated with worse OS in univariable (HR = 1.05; 95% C.I. = 1.02, 1.09; p = 0.002) but not in multivariable analysis and did not correlate with increased TIL infiltration. Combined TIL weighted score was a significant independent prognostic factor for OS and DSS, (HR = 0.95; 95% C.I. = 0.93, 0.98; p = 0.0003 and HR = 0.96; 95% C.I. = 0.93, 0.99; p = 0.005, respectively). All of the biomarkers (p53, p21, p16, TILs) differed by HPV status and tumor site (p < 0.0001 each). Further analysis by specific tumor site was unremarkable for an association between p53 expression and TILs or prognosis. However, in multivariable analysis for oropharynx cancer, p53 expression was associated with increased risk of death (HR 2.33; 95% C.I. = 1.00, 5.43; p = 0.05) and in particular for the p16 negative oropharyngeal subgroup (HR = 8.62, 95%; C.I. = 1.94, 38.4; p = 0.005). Conclusions: Over-expression of p53 is an unreliable biomarker for prognosis and does not correlate with levels of TILs suggesting that p53 neoantigens are unlikely to be useful targets for future immunotherapy. These findings were confirmed when patients were analyzed by specific tumor site, however in the subset of HPV-negative oropharyngeal cancers, p53 expression was associated with treatment outcomes and could be a useful biomarker. (43","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"142 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76627044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Aggressive Management of Postoperative Pancreatic Fistulas following Pancreaticoduodenectomy (PD): A Five-Year Single Institution Experience","authors":"Thakkar Rohan G, Msc David Bourne,, Vass Stacey, K. Aditya, Tsirilis Theodore, Hammond John S, W. Colin, Sen Gourab, W. Steven, French Jeremy, C. Richard, Manas Derek","doi":"10.23937/2378-3419/1410121","DOIUrl":"https://doi.org/10.23937/2378-3419/1410121","url":null,"abstract":"Background: Pancreatico-duodenectomy for pancreatic tumours remains the standard of care. Morbidity rates are still high, often as a result of post-operative pancreatic fistulae (POPF), leading to prolonged hospital stays and increased costs. At our institute we treat all pancreatic fistulas defined by ISGPF criteria with parenteral nutrition and an octreotide infusion for a minimum of 7 days. Our experience suggests that early and aggressive management of POPF could prevent Grade C fistulas. Methods: We retrospectively analysed the data that underwent PD between 2013-2017. We reviewed for all patients who experienced Grade B POPF. Data included details of total parenteral nutrition received, dose of octreotide infusion administered, serial drain amylase levels, effluent volume and anthropometry. Outcome measures were weight changes associated with treatment, the number of lines used per patient, the length of treatment, treatment associated complications and 90-day mortality rates. Results: 53 patients had a Grade B POPF and all were treated with the ‘leak protocol’. The Grade B pancreatic fistulas rate was 13%. Median ages of the patients were 69. Median hospital stay was 30.5 days. Parenteral nutrition was administered for an average of 20 days. The mean BMI on discharge was 26.5 with an average weight difference of -4.9%. There was one 90-day operative mortality. 2 patients had Grade C fistulas requiring re-operation. Conclusions: Our institutional practice has good results with a Grade C POPF incidence of 0.4% that is much lower than what is in literature. We think this management of pancreatic leaks have promising results.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88359900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of Three Prognostic Models in Critically Ill Patients with Cancer: A Prospective Study","authors":"Martos-Benítez Frank D, Larrondo-Muguercia Hilev, L. David, Rivero-López Juan C, Orama-Requejo Versis, Martínez-Alfonso Jorge L","doi":"10.23937/2378-3419/1410120","DOIUrl":"https://doi.org/10.23937/2378-3419/1410120","url":null,"abstract":"Background: The aim of the study was to evaluate the performance of “Acute Physiology and Chronic Health Evaluation II” (APACHE-II), “Simplified Acute Physiology Score 3” (SAPS-3), and “APACHE-II Score for Critically Ill Patients with a Solid Tumor” (APACHE-IICCP) models in cancer patients admitted to ICU. Methods: Prospective cohort study of 414 patients with an active solid tumor. Discrimination was assessed by area under receiver operating characteristic (AROC) curves and calibration by Hosmer–Lemeshow goodness-of-fit C test (H–L). Results: The hospital mortality rate was 32.6%. In the total cohort, discrimination was superior for APACHE-IICCP model (AROC 0.98) compared to APACHE-II (AROC 0.96), SAPS-3 (AROC 0.91), and SAPS-3 for Central and South American countries (SAPS-3CSA) (AROC 0.95) models. Calibration was good (p-valueof H–L test > 0.05) using APACHE-IICCP, APACHE-II and SAPS-3CSA models. Estimation of the probability of death was more precise with APACHE-IICCP model (standardized mortality ratio, SMR = 1.03). Further analysis showed that discrimination was better with APACHE-IICCP model than with APACHE-II, SAPS-3, and SAPS-3CSA models whether for patients with planned ICU admission (AROC 0.97 vs. 0.96, 0.95 and 0.95, respectively) or for patients with unplanned ICU admission (AROC 0.97 vs. 0.94, 0.86 and 0.95). When the SMR and calibration were analyzed, the APACHE-IICCP model was the only model to provide predicted mortality rates closer to the observed mortality for patients with planned and for patients with unplanned ICU admission. Conclusions: In this prospective study, APACHE-IICCP model was superior to APACHE-II, SAPS-3, and SAPS3CSA models in predicting hospital mortality.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82385874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Αβ-Crystallin and Laminin-332 are Prognostic Markers for Triple Negative Breast Cancers in a Brazilian Series","authors":"M. Graudenz, D. Uchoa, E. Cadore, J. Giacomazzi, S. Callegari-Jacques","doi":"10.23937/2378-3419/1410103","DOIUrl":"https://doi.org/10.23937/2378-3419/1410103","url":null,"abstract":"Purpose: Association between increased αβ-crystallin (ABC) and abnormal LN332 (LN332) expression in triple negative (TNBC) and basal-like (BLBC) breast cancers has been suggested recently. This study aims to evaluate ABC and LN332 immunohistochemical expression in a series of TN infiltrating ductal breast carcinomas and its association with clinical-pathological features and prognostic significance. Methods: Microarrays of 69 cases of TNBC cases were scored for the expression of ABC, LN332, CK5/6 and EGFR by immunohistochemistry with linked clinical and pathological data (age, tumor size, lymph node metastases, histological grade and subtype, lymphovascular invasion). Tumors were scored as strong, moderate and weakly positive for these biomarkers. Results: ABC was expressed in 72.7% (48/66) and LN332 in 63.8% (44/69) of cases. ABC immunostaining was predominantly cytoplasmic (73.5%) and LN332 was exclusively cytoplasmic (100%). ABC was expressed in 83% of BLBC, followed by the penta negative profile (17%). The 5-year survival was 0.67 and 0.75 for ABC negative and LN332 positive tumors, respectively. For the BLBC group this probability was 0.67, while in the penta negative group (ABC, LN332, CK5/6 and EGFR) it was only 0.37. ABC-/LN332+ profile was associated with longer probability of non-recurrence (10-years probability: 0.86 for ABC-/LN332+ tumors versus 0.36 for other profiles; P = 0.021) and longer cumulative survival (10-years probability: 1.0 for ABC-/LN332+ tumors versus 0.53 for other profiles; P = 0.031). There was no association between the ABC-negative/LN332-positive profile and BLBC. Conclusions: ABC and LN332 are commonly expressed in TNBC, especially in BLBC. TNBC with ABC-/LN332+ profile showed better clinical outcome.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"106 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85392025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exemestane-Induced Eosinophilic Colitis in a Patient with Grade 3 Ductal Carcinoma In-Situ: A Case Report and Review of the Literature","authors":"Sanders Kristyn, L. Shannon, R. Ortega, G. Mark, M. Lida","doi":"10.23937/2378-3419/1410104","DOIUrl":"https://doi.org/10.23937/2378-3419/1410104","url":null,"abstract":"Purpose: A case report of eosinophilic colitis associated with exemestane use is presented. Summary: Approximately after three months of exemestane therapy for breast cancer risk reduction, a 60-year-old female with estrogen receptor positive, right breast ductal carcinoma in situ (DCIS) presented to the emergency room with severe abdominal pain, nausea, vomiting, and diarrhea. Imaging studies revealed severe colitis of the transverse colon. No other medications were started except for exemestane that would have contributed to the patient’s symptoms. Outpatient workup included stool cultures, laboratory studies, and esophagogastroduodenoscopy and colonoscopy with biopsies. Results of the studies were significant for eosinophilic colitis and moderate to borderline severe colitis with increased eosinophilia. The patient was subsequently started on corticosteroids and discontinued exemestane. Her symptoms resolved in two weeks. Approximately two months later, the patient was started on tamoxifen for breast cancer prevention, which she tolerated well. Conclusion: Exemestane was deemed the probable cause of the acute episode of eosinophilic colitis in this case. One other prior case with aromatase inhibitor-induced eosinophilic colitis has been reported with letrozole, however this is the first case report of eosinophilic colitis associated with exemestane. Background Exemestane is an irreversible, steroidal aromatase in-activator that structurally resembles androstenedione [1]. The pharmacological activity of exemestane is centered on the conversion of the drug to an intermediate that irreversibly blocks the active site of aromatase thereby rendering the enzyme permanently inactivated [1]. The inactivation of aromatase results in lower levels of circulating hormones that can increase the growth and size of hormone receptor positive breast cancers [1]. Exemestane first received FDA approval in the United States in 1999 for the treatment of advanced breast cancer in post-menopausal women whose tumors have stopped responding to tamoxifen [2]. Currently, it is approved for: the adjuvant treatment of postmenopausal women with estrogen receptor positive early stage breast cancer who have received two to three years of tamoxifen (an estrogen receptor antagonist) and are switched to exemestane for completion of a total of five years of adjuvant hormonal therapy [1,3,4]. It is also approved for advanced breast cancer in women whose disease has progressed following tamoxifen [1]. The American Society of Clinical Oncology (ASCO) clinical practice guidelines also recommends the use of ISSN: 2378-3419 DOI: 10.23937/2378-3419/1410104 Sanders et al. Int J Cancer Clin Res 2019, 6:104 • Page 2 of 5 • ductal carcinoma in situ with mastectomy were included [13]. Exemestane was found to reduce invasive breast cancer in postmenopausal women who were found to be at moderately increased risk for breast cancer [13] (Table 1). Exemestane is overall well tolerated with side e","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88855216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a Dedicated Multidisciplinary Research and Treatment Network on Outcomes of Muscle-Invasive Bladder Cancer Patients","authors":"Robbrecht Debbie G, Verhoeven Rob HA, Vries Peter de, Heijden Michiel S van der, Boormans Joost L, Wit Ronald de","doi":"10.23937/2378-3419/1410105","DOIUrl":"https://doi.org/10.23937/2378-3419/1410105","url":null,"abstract":"Background: The Dutch Uro-Oncology Study Group (DUOS) is a multidisciplinary network of ~30 hospitals involved in research and treatment of urological cancers. We analyzed the influence of treatment at DUOS versus non-DUOS on survival of muscle-invasive bladder cancer (MIBC) patients and explored correlating parameters. Patients and methods: Characteristics of 3472 cT24aN0/XM0 MIBC patients who underwent radical cystectomy (RC), with or without neoadjuvant chemotherapy (NAC), were collected by the Netherlands Cancer Registry (NCR). 5-year overall survival (OS) was estimated by the Kaplan-Meier method. Cox regression analyses were performed to determine hazard ratios for pre-defined variables. Results: 5-year OS differed 3.2% in favor of DUOS centers (49.3% vs. 46.1%, p = 0.09). Best survival was observed in patients treated with NAC and RC at DUOS centers (5year OS 57%). This was 61.1% in cT3-4 patients treated at DUOS centers. NAC was only significantly associated with improved survival in cT3-4a patients treated at DUOS centers (p = 0.0002). Positive surgical margins were less frequent (p = 0.02) and more pelvic lymph nodes (LNs) were collected and identified (p = 0.001) at DUOS centers. Surgical margins, number of identified LNs, and number of positive LNs significantly correlated with OS. Conclusions: We identified a greater survival benefit by the use of NAC, a higher number of LNs identified, a lower rate of positive surgical margins and a trend towards survival benefit in patients treated at centers that collaborate in the multidisciplinary DUOS national network. Implications for practice: Our retrospective analysis based on 3472 muscle-invasive bladder cancer patients, showed a non-significant trend towards survival benefit when treated in hospitals involved in a national study-group network (DUOS), with significantly superior outcomes concerning neo-adjuvant chemotherapy, surgical margins and lymph node dissection. These factors significantly correlated with an improved survival, favoring treatment at centers that are involved in a multidisciplinary national network with dedicated care for bladder cancer.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84595096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Awareness Level, Knowledge and Attitude towards Breast Cancer between Medical and Non-Medical University Students in Makkah Region: A Cross Sectional Study","authors":"Sindi Ramya Ahmad, Alzahrani Asmaa Ahmad, Alzahrani Nesreen Abdullah, Salman Rana Ahmad Bin, Alshareef Shaimaa Amer, T. Aisha, I. Shahid","doi":"10.23937/2378-3419/1410106","DOIUrl":"https://doi.org/10.23937/2378-3419/1410106","url":null,"abstract":"Background: Breast cancer is the most common cancer among Saudi Arabian females followed by cancer of thyroid and colorectum. Objective: To assess the awareness level, knowledge and attitude of female medical students and non medical university students in the Makkah region.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75326176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Single Institution Study Experience of Secondary Breast Angiosarcoma after Breast Conserving Treatment: Multidisciplinary Management","authors":"Strazzanti Angela, Trovato Claudio, G. Santi, Marletta Dario, Milazzotto Roberto, S. Corrado","doi":"10.23937/2378-3419/1410114","DOIUrl":"https://doi.org/10.23937/2378-3419/1410114","url":null,"abstract":"The aim of this study, focusing on a small number of cases, is to deal with the angiosarcoma of the breast, representing less than 1% of all soft tissue breast tumors, and finally share our experience. As a consequence of breast-conserving therapy (BCT) that is the standard treatment nowadays, a new type of angiosarcoma has been highlighted: RadiationInduced Angiosarcoma (RIAS). Here is reported a retrospective analysis of RIAS patients’ characteristic features, together with an account of the integrated treatment and the outcome of six cases of RIAS treated in our institution from 2013 to 2018. Breast angiosarcoma as a consequence of surgery and radioterapy has been rarely recorded but it is a documented complication of radiation treatment for breast cancer, with a high recurrence rate and poor outcomes. It remains challenging clinically, radiologically and histologically, and thus a high index of suspicion is required in susceptible patients. Simple mastectomy is the primary treatment option, however, an increasing number of studies on the use of radiotherapy and chemotherapy, each with variable degree of success, is being focused. Re-irradiation can be taken into consideration in order to increase local control, while chemotherapy may be considered for cases in a more advanced stage.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76090085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Nephroblastoma in Developing Countries - Experience from a Single Center in Vietnam with NWTS 5 and SIOP 2001 Protocols","authors":"T. Duc, X. HoangBa","doi":"10.23937/2378-3419/1410113","DOIUrl":"https://doi.org/10.23937/2378-3419/1410113","url":null,"abstract":"","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79490870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunology of the Spontaneous Remission of Cancer","authors":"Niakan Behzad","doi":"10.23937/2378-3419/1410112","DOIUrl":"https://doi.org/10.23937/2378-3419/1410112","url":null,"abstract":"Citation: Niakan B (2019) Immunology of the Spontaneous Remission of Cancer. Int J Cancer Clin Res 6:112. doi.org/10.23937/2378-3419/1410112 Accepted: April 23, 2019; Published: April 25, 2019 Copyright: © 2019 Niakan B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75282299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}